Last update Jan. 6, 2021

Letermovir

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Antiviral prescribed for profilaxis from cytomegalovirus (CMV) infeccion in recipients of allogeneic hematopoietic stem cell transplants.
Administered orally or intravenously once a day.

We could not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

Due to its pharmacokinetic data (large distribution volume, moderately high molecular weight and very high protein binding percentage: EMA 2018), it is very unlikely for any significant amounts to pass into human milk.

When it is not combined with ciclosporin, its low oral bioavailability (35%: EMA 2018) makes it very difficult for this substance to reach a breastfeeding infant´s plasma. There may be greater intestinal permeability in preterm infants and during the immediate neonatal period but even then the amount that could pass into breast milk would still be clinically negligible.


See below the information of this related product:

Alternatives

  • Ganciclovir (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Letermovir in other languages or writings:

Group

Letermovir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Letermovir in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 35 (+CP: 85) %
Molecular weight 573 daltons
Protein Binding 99 %
VD 0,65 l/Kg
pKa 3,75 - 7,15 -
Tmax 0,75 - 2,25 hours
T1/2 12 hours

References

  1. EMA. Letermovir. Ficha técnica. 2018 Full text (in our servers)
  2. EMA. Letermovir. Drug Summary. 2018

Total visits

3,245

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM